secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001437749-22-022390
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%
------------------------------------------------------------------------------

- Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.
- Full fiscal year revenue $56.2M, down 11.6% from $63.6M; operating income $2.7M vs $5.8M.
- Full year diluted EPS $0.12 vs $0.25; net income $3.8M vs $8.0M.
- Co-CEOs cite normalization after pandemic-driven safety stock and demand as reasons for decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/0001437749-22-022390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/inbp20220913_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-022390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer